Trial reportJournal of hypertension2014
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension.
Trial report in Journal of hypertension, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta-Analysis.Journal of the American Heart Association · 2024Pooled it
- Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.Hypertension (Dallas, Tex. : 1979) · 2018Guideline
- The role of clinical pharmacist in the management of resistant hypertension.Irish journal of medical science · 2025Trial
- Trial
- Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering.Journal of clinical hypertension (Greenwich, Conn.) · 2019Trial
- Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension.Journal of the American Society of Hypertension : JASH · 2016Trial
- Lifestyle modification for resistant hypertension: The TRIUMPH randomized clinical trial.American heart journal · 2015Trial
- Contemporary Prevalence and Treatment Patterns Among US Adults With Apparent Treatment-Resistant Hypertension.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Apparent treatment-resistant hypertension in ambulatory hypertensive patients in Northeast Ethiopia: prevalence, treatment patterns, and predictors.BMC cardiovascular disorders · 2026Article
- Characterizing Alzheimer's Disease and Related Dementia in a Hypertension Population Within the State of Florida Using Electronic Health Record-Based Data.Clinical pharmacology and therapeutics · 2026Article
- Fixed-dose combinationFrontiers in pharmacology · 2026Article
- Incidence and prognosis of apparent-treatment resistant hypertension: a multi-state analysis using real world evidence.Clinical hypertension · 2026Article
- Predictive Factors of Apparent Treatment Resistant Hypertension Among Patients With Hypertension Identified Using Electronic Health Records.Journal of general internal medicine · 2025Article
- Characterizing apparent treatment resistant hypertension in the United States: insights from the All of Us Research Program.Journal of the American Medical Informatics Association : JAMIA · 2024Article
- Prevalence, Clinical Characteristics, and Treatment of Patients with Resistant Hypertension: A Single-Center Study.Journal of cardiovascular development and disease · 2024Article
- ATP2B1 gene polymorphisms associated with resistant hypertension in the Japanese population.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- Review
- Laparoscopic adrenalectomy performed by a general surgeon on functioning adrenal tumors: Treatment outcomes and risk prediction of persistent hypertension.Qatar medical journal · 2024Article
- Prevalence, Risk Factors and Cardiovascular Comorbidities of Resistant Hypertension among Treated Hypertensives in a Nigerian Population.Global heart · 2024Article
- Duration-sensitive association between air pollution exposure and changes in cardiometabolic biomarkers: Evidence from a predominantly African American cohort.Environmental research · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
objectiveResistant hypertension (res-HTN) is a challenging problem, but little is known of res-HTN in patients with coronary artery disease (CAD). In this post-hoc INternational VErapamil SR-Trandolapril STudy (INVEST) analysis, we assessed prevalence, predictors, and impact on outcomes of res-HTN in CAD patients with hypertension.
methodsParticipants (n=17190) were divided into three groups according to achieved blood pressure (BP): controlled (BP <140/90 mmHg on three or fewer drugs); uncontrolled (BP ≥ 40/90 mmHg on two or fewer drugs); or resistant (BP ≥ 40/90 mmHg on three drugs or any patient on at least four drugs).
resultsThe prevalence of res-HTN was 38%: significant predictors of res-HTN included heart failure [odds ratio (OR) 1.73], diabetes (OR 1.63), Black race (OR 1.50), and US residence (OR 1.50). Compared with controlled HTN, res-HTN had multivariate-adjusted association with higher risk of adverse outcomes {first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke [hazard ratio 1.27, 95% confidence interval (CI) 1.13-1.43], and individual outcomes of all-cause death (hazard ratio 1.29, 95% CI 1.13-1.48), cardiovascular mortality (hazard ratio 1.47, 95% CI 1.21-1.78), and nonfatal stroke (hazard ratio 1.61, 95% CI 1.17-2.22), but not nonfatal myocardial infarction (hazard ratio 0.98, 95% CI 0.72-1.34)}. Adverse outcomes, except nonfatal stroke, did not differ in patients with res-HTN compared to uncontrolled HTN.
conclusionsRes-HTN is common in patients with CAD and hypertension, associated with poor prognosis, and linked with a number of conditions. Emphasis should be placed on recognizing those at risk for res-HTN and future studies should examine whether more aggressive treatment of res-HTN improves outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.